Form 4 for APRE Aprea Therapeutics, Inc.
Accepted 2023-08-24 00:00:00 ET · period of report 2023-08-23 · accession 0001104659-23-095016 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-24 | 2023-08-23 | APRE | Seizinger Bernd R. | Dir | A - Grant | $0.00 | +500 | 26.8K | +2% | $0 |
| D | 2023-08-24 | 2023-08-23 | APRE | Seizinger Bernd R. | Dir | A - Grant | $0.00 | +2,000 | 2,000 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-23 | A | A | 500 | $0.00 | 26,825 | D | — | — | (F1) These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |
| 2 | Derivative | Stock Options (Right to Buy) | 2023-08-23 | A | A | 2,000 | $0.00 | 2,000 | D | $3.65 · — to 2033-08-23 | 2,000 Common Stock | (F2) The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions. |